Understanding RILP: Potential Drug Targets Or Biomarkers (G83547)

Target Name: RILP

NCBI ID: G83547

RILP

Other Name(s): RILP_HUMAN | FLJ31193 | Rab-interacting lysosomal protein | Rab interacting lysosomal protein | PP10141

Understanding RILP: Potential Drug Targets Or Biomarkers

RNA-Induced Proteasome Hypersensitivity (RILP) is a cellular stress response pathway that plays a crucial role in the regulation of cell survival and growth. The protein human RILP (RILP_HUMAN) is a key player in this pathway and has been identified as a potential drug target or biomarker.

RILP is a 24-kDa protein that is expressed in various tissues and cells, including the brain, heart, liver, and muscle. It is composed of a N-terminal transmembrane domain, a cytoplasmic domain, and an C-terminal protein domain. The cytoplasmic domain contains the major functional regions of the protein, including a catalytic site, a binding site, and a regulatory site.

The N-terminal transmembrane domain is responsible for the protein's intracellular localization and its ability to interact with various signaling molecules. This domain also contains a critical hydrophobic region that is involved in the protein's stability and stability in the cytoplasm.

The C-terminal protein domain is the largest and most complex region of RILP. It contains a unique structural feature called a variable region, which is composed of a series of 11 non-overlapping subdomains. The variable region is responsible for the protein's unique activity and stability.

The RILP pathway is involved in the regulation of cellular stress responses, including the response to DNA damage, UV radiation, and certain drugs. It is well established that the RILP pathway is activated in response to these stressors and that it plays a role in the regulation of cell survival and growth.

The RILP protein is involved in the regulation of several cellular processes, including cell division, cell growth, and apoptosis. It is a positive regulator of the G1 cell growth checkpoint, which is responsible for the regulation of cell cycle progression. It is also a negative regulator of the G2/M cell cycle checkpoint, which is responsible for the regulation of cell division.

The RILP protein is also involved in the regulation of cell apoptosis. Research shows that RILP plays a role in the regulation of cell apoptosis and that its activity is regulated by several factors, including DNA damage, UV radiation, and certain drugs.

The RILP protein is a potential drug target or biomarker due to its involvement in several cellular processes that are important for human health and disease. The RILP pathway is involved in the regulation of cell stress responses, including the response to DNA damage, UV radiation, and certain drugs. The RILP protein is involved in the regulation of several cellular processes, including cell division, cell growth, and apoptosis.

The RILP protein is a positive regulator of the G1 cell growth checkpoint and a negative regulator of the G2/M cell cycle checkpoint. It is also involved in the regulation of cell apoptosis and its activity is regulated by several factors, including DNA damage, UV radiation, and certain drugs.

In conclusion, the RILP protein is a key player in the RILP pathway and has several potential drug targets or biomarkers. Further research is needed to fully understand the role of RILP in cellular stress responses and its potential as a drug target or biomarker.

Protein Name: Rab Interacting Lysosomal Protein

Functions: Rab effector playing a role in late endocytic transport to degradative compartments (PubMed:11696325, PubMed:14668488, PubMed:27113757, PubMed:11179213, PubMed:12944476). Involved in the regulation of lysosomal morphology and distribution (PubMed:14668488, PubMed:27113757). Induces recruitment of dynein-dynactin motor complexes to Rab7A-containing late endosome and lysosome compartments (PubMed:11179213, PubMed:11696325). Promotes centripetal migration of phagosomes and the fusion of phagosomes with the late endosomes and lysosomes (PubMed:12944476)

The "RILP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RILP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets